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Antimicrobial activityAbstract Because of the highly therapeutic nature of 1,2,4-triazoles, a new class of fused pyrazolo
[30,40:4,5] thiazolo [3,2-b] [1,2,4]-triazole, isoxazolo [30,40:4,5] thiazolo [3,2-b] [1,2,4]-triazole moieties
were prepared from the novel conventional methods via the reaction of 4-methyl benzoyl thiosem-
icarbazide with the appropriate chemical reagents. These compounds were screened for their anti-
microbial activity against various bacterial and fungal strains. With the reference of antimicrobial
activity data the synthesized compounds were further screened for their antimycobacterial activity
against Mycobacterium tuberculosis H37Rv by the conventional methods. Among the synthesized
compounds 4b, 4d, 4h, 5d and 5h have shown more activity compared to the standard drugs.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The rapid development of mycobacterial resistance to conven-
tional drugs is one of the major difﬁculties in the treatment of
tuberculosis. The incidence of tuberculosis is increasing world-
wide, partly due to poverty and inequity and partly to the
HIV/AIDS pandemic, which greatly increase the risk of infec-
tion proceeding to overt disease. Moreover the development
of drug resistant strains of mycobacterium species, has contrib-
uted to the inefﬁciency of the conventional antituberculosis
therapy, thus it is still necessary to search for new antimicrobialagents. Since the discovery of hetero cyclic nucleus the chemistry
of 1,2,4-triazoles and their fused heterocyclic derivatives repre-
sent an interesting class of compounds possessing a wide spec-
trum of biological activities. The huge number of 1,2,4-
triazoles containing systems exhibits anti-inﬂammatory activity
(Mullican et al., 1993; Tozkoparan et al., 2007), antibacterial
(Foroumadi et al., 2003), antimycobacterial (Kucukguzel
et al., 2001), anticonvulsant (Kelley et al., 1995), antifungal
(Heubach et al., 1979), antidepressant (Chiu and Huskey,
1998), and plant growth regulator anti coagulants (Eliott
et al., 1987). On the other hand thiazoles are also a familiar class
of heterocyclic compounds possessing a wide variety of biolog-
ical activities and their utility in medicine is very much estab-
lished (Andrew et al., 2008). Several physiological activities of
various thiazole derivatives have proved the efﬁcacy and efﬁ-
ciency in combating various diseases and noticed to have good
therapeutic agents such as anti tubercular agents (E1-Shaaer
et al., 1998), antimicrobial agents (Gouda et al., 2010; Liaras
et al., 2011), anti-Candida spp. agents (Chimenti et al., 2011).
412 N. Seelam et al.Furthermore, diverse chemotherapeutic activities have been as-
cribed to fused 1,2,4-triazolo thiazole moieties as antimicrobial
agents (Guzeldemirci and Kucukbasmac, 2010). Literature sur-
vey revealed that somepyrazoles have been implemented as anti-
viral (Genin et al., 2000), antimicrobial (Foks et al., 2005;
Prakash et al., 2008), anti-neoplastic (Farag et al., 2008), anti-tu-
mour (Xia et al., 2008) and analgesic agents (Khode et al., 2009).
In view of these above ﬁndings it was contemplated to de-
sign and synthesize a new class of heterocyclic derivatives in
which 1,2,4-triazole, pyrazolo-thiazole or isoxazolo-thiazole
derivatives in a single molecular frame work act as antimicro-
bial and anti tuberculosis agents.
2. Experimental
All melting points were measured on the open capillary meth-
od. IR spectra were recorded for KBr disc on Schimadzu-8400
FTIR spectrophotometer. 1H NMR, 13C NMR spectra were
measured on a Bruker Avance II 400 spectrometer, operating
at 400, 100.6 MHz respectively. Chemical shifts (d) are re-
ported in parts per million (ppm) and TMS as an internal stan-
dard. Molecular weights were determined with TOF MS ES
Mass spectra. Reactions were monitored by thin layer chroma-
tography (TLC) on silica gel, plates were visualized with ultra-
violet light or iodine. Column chromatography was performed
on silica gel 60(0.043–0.06 mm) Merck.
2.1. 4-Methyl benzoyl thiosemicarbazide (1)
A mixture of Ethyl-p-methyl-benzoate (0.01 mol) and thiosem-
icarbazide (0.01 mol) in methanol (25 ml) was reﬂuxed for
10 h. The solvent was removed under reduced pressure and
the viscous mass poured over ice water, ﬁltered and recrystal-
lized from methanol–water to afford compound 1.
2.2. 5-Mercapto-3-p-tolyl-s-triazole (2)
P-methyl benzoyl thiosemicarbazide (2 g) in 8% NaOH Solu-
tion (30 ml) was heated under reﬂux temperature for 5 h.
The reaction mixture was cooled to room temperature and
acidiﬁed with dil. acetic acid. The product thus separated
was ﬁltered, washed with excess of water and recrystallized
from ethanol to afford compound 2.
2.3. (Z)-5-(substituted-benzylidene)-2-(p-tolyl) thiazolo [3,2-
b] [1,2,4] triazol-6(5H)-one (3)
A mixture of compound 2 (0.01 mol), chloro acetic acid
(0.01 mol), appropriate aromatic aldehyde (0.01 mol) fused so-
dium acetate (0.02 mol) in acetic anhydride (20 ml) and glacial
acetic acid (30 ml) was reﬂuxed on a heating mantle for 4 h,
concentrated and cooled. The brown solid separated was ﬁl-
tered, washed well with water and recrystallized from glacial
acetic acid as brown crystals. The compounds 3a–h were pre-
pared similarly by treating with corresponding aldehydes.
2.3.1. 3-Phenyl-6-(p-tolyl)-3, 3a-dihydro-2H-pyrazolo
[30,40:4,5] thiazolo [3,2-b] [1,2,4] triazole (4a)
A mixture of compound 3 (0.005 mol), hydrazine hydrate
(0.005 mol) and anhydrous CH3COONa (0.01 mol) in glacialacetic acid was heated under reﬂux conditions for 5 h, cooled to
room temperature and poured into ice cold water. The dark brown
solid thus separated was ﬁltered, washed with excess of water and
recrystallized fromaceticacid toobtain thedesiredcompound.Yield
61.8%, m.p. 218–220 C; IR (KBr) in cm1: 3325.39, 3078.49,
3064.99, 2951.23, 1558.54, 1236.41, 1030.02, 698.25; 1H NMR
(400MHz, DMSO-d6) d ppm: 7.01–7.45 (m, 9H, Ar–H), 7.87 (s,
1H, N–H), 4.99 (d, 1H, N–CH), 4.47 (d, 1H, S–CH), 2.81 (s, 3H,
CH3);
13C NMR (DMSO-d6) d ppm: 22.17, 41.3, 53.8, 121.8,
126.1, 128.5, 139.4, 147.2, 157.9; MS: m/z 334.38 [M+1].
The other compounds (4b–h) were also prepared similarly
by treating with corresponding compounds 3b–h. The physical
and analytical data were given in Table 1.
2.3.2. 3-(4-Chlorophenyl)-6-(p-tolyl)-3, 3a-dihydo-2H-pyrazolo
[30,40:4,5] thiazolo[3,2-b] [1,2,4]-triazole (4b)
Yield 64.7%, m.p. 254–257 C; IR (KBr) cm1: 3296.18,
3078.49, 3064.99, 2953.11, 1600.97, 1558.54, 1236.41,
1107.18; 1H NMR (400 MHz, DMSO-d6) d ppm: 7.91 (s, 1H,
N–H), 7.09–7.41 (m, 6H, Ar–H), 7.01 (d, 2H, Ar–H near-
Cl), 4.99 (d, 1H, N–CH), 4.32 (d, 1H, S–CH), 2.69 (s, 3H,
CH3);
13C NMR (DMSO-d6) d ppm: 22.7, 41.3, 53.6, 131.2,
118.3, 127.5, 130.1, 147.2, 156.5; MS: m/z 369.21 [M+ 2],
368.38 [M+1].
2.3.3. 3-(3-Nitrophenyl)-6-(p-tolyl)-3, 3a-dihydo-2H-pyrazolo
[30,40:4,5] thiazolo[3,2-b] [1,2,4]-triazole (4c)
Yield-62.5%, m.p. 219–222 C; IR (KBr) cm1: 3294.23,
3078.49, 3065.57, 2953.11, 1600.97, 1551.58, 1528.04, 1236.41;
1H NMR (400 MHz, DMSO-d6) d ppm: 8.01 (s, 1H, N–H),
7.69 (d, 2H, Ar–H near NO2), 7.03–7.41 (m, 6H, Ar–H), 5.09
(d, 1H, N–CH), 4.51 (d, 1H, N–CH), 2.78 (s, 3H, CH3);
13C
NMR (DMSO-d6) d ppm: 22.7, 41.3, 53.6, 119.6, 129.3, 133.7,
138.3, 147.2, 149.03, 156.9; MS: m/z 379.46 [M+1].
2.3.4. 3-(4-Nitrophenyl)-6-(p-tolyl)-3, 3a-dihydo-2H-pyrazolo
[30,40:4,5] thiazolo[3,2-b] [1,2,4]-triazole (4d)
Yield-64.1%, m.p. 267–269 C; IR (KBr) cm1: 3296.08,
3071.12, 3065.57, 2953.11, 1600.97, 1558.19, 1521.86; 1H
NMR (400 MHz, DMSO-d6) d ppm: 8.01 (s, 1H, N–H), 7.69
(d, 2H, Ar near NO2), 7.12–7.53 (m, 6H, Ar–H), 5.06 (d,
1H, N–CH), 4.57 (d, 1H, S–CH), 2.42 (s, 3H, CH3);
13C
NMR (DMSO-d6) d ppm: 22.7, 41.3, 53.6, 119.6, 129.3,
134.2, 138.3, 146.9, 149.1, 157.41; MS: m/z 379.53 [M+1].
2.3.5. 3-(2-Methoxyphenyl)-6-(p-tolyl)-3, 3a-dihydo-2H-
pyrazolo [30,40:4,5] thiazolo[3,2-b] [1,2,4]-triazole (4e)
Yield-59.7%, m.p. 237–239 C; IR (KBr) cm1: 3287.11,
3071.12, 3065.68, 2959.45, 1600.97, 1558.16, 1249.98,
1236.41; 1H NMR (400 MHz, DMSO-d6) d ppm: 7.91 (s, 1H,
N–H), 7.1–7.46(m, 7H, Ar–H), 6.85 (d, 1H, Ar–H near
OCH3), 4.96 (d, 1H, N–CH), 4.67 (d, 1H, S–CH), 3.38 (s,
3H, OCH3), 2.69 (s, 3H, CH3);
13C NMR (DMSO d6) d ppm;
22.3, 41.3, 53.1, 55.8, 115.7, 127.4, 136.9, 147.2, 158.1, 159.6;
MS: m/z 364.33 [M+1].
2.3.6. 3-(4-Methoxyphenyl)-6-(p-tolyl)-3, 3a-dihydo-2H-
pyrazolo [30,40:4,5] thiazolo[3,2-b] [1,2,4]-triazole (4f)
Yield. 61.3%, m.p. 258–260 C; IR (KBr) cm1: 3287.11,
3071.49, 3065.68, 2954.81, 1600.97, 1543.27, 1249.98,
Table 1 Physical and analytical data of synthesized compounds 4a–h and 5a–h.
Comp0d R Yield (%) m.p. (C) Mol. Formula/(M.wt) C, H, N analysis (calcd/found)
C H N
4a H 61.8 218–220 C18H15N5S/333.41 64.84 4.53 21.01
(64.87) (4.49) (21.05)
4b 4-Cl 64.7 254–257 C18H14ClN5S/367.86 58.77 3.84 19.04
(58.74) (3.87) (19.00)
4c 3-NO2 62.5 219–222 C18H14N6 O2S/378.41 57.13 3.73 22.21
(57.09) (3.69) (22.25)
4d 4-NO2 64.1 267–269 C18H14N6 O2S/378.41 57.13 3.73 22.21
(57.10) (3.77) (22.24)
4e 2-OCH3 59.7 237–239 C19H17N5 OS/363.44 62.79 4.71 19.27
(62.83) (4.75) (19.31)
4f 4-OCH3 61.3 258–260 C19H17N5 OS/363.44 62.79 4.71 19.27
(62.75) (4.74) (19.30)
4g 4-N(CH3)2 63.5 241–243 C20H20N6S/376.48 63.81 5.35 22.32
(63.84) (5.39) (22.36)
4h 4-Br 58.6 226–228 C18H14BrN5S/412.31 52.43 3.42 16.99
(52.48) (3.46) (16.95)
5a H 68 249–251 C18H14N4zOS/334.39 64.65 4.22 16.75
(64.69) (4.18) (16.79)
5b 4-Cl 67.1 265–267 C18H13ClN4OS/368.84 58.61 3.55 15.19
(58.66) (3.59) (15.23)
5c 3-NO2 69.5 225–227 C18H13N5 O3S/379.39 56.98 3.45 18.46
(57.02) (3.49) (18.50)
5d 4-NO2 70.1 261–263 C18H13N5 O3S/379.39 56.98 3.45 18.46
(56.95) (3.49) (18.51)
5e 2-OCH3 65.6 241–243 C19H16N4 O2S/364.42 62.62 4.43 15.37
(62.66) (4.47) (15.33)
5f 4-OCH3 68 273–275 C19H16N4 O2S/364.42 62.62 4.43 15.37
(62.67) (4.47) (15.41)
5g 4-N(CH3)2 71 256–258 C20H19N5 OS/377.46 63.64 5.07 18.55
(63.68) (5.03) (18.59)
5h 4-Br 60.8 218–220 C18H13BrN4 OS/413.29 52.31 3.17 13.56
(52.27) (3.22) (13.60)
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N–H), 7.08–7.48 (m, 6H, Ar–H), 6.93 (d, 2H, Ar–H near
OCH3), 4.99 (d, 1H, N–CH), 4.67 (d, 1H, S–CH), 3.38 (s,
3H, OCH3), 2.73 (s, 3H, CH3);
13C NMR (DMSO-d6) d ppm;
22.5, 40.91, 53.6, 55.8, 115.7, 127.3, 136.1, 147.3, 158.1, 159.6;




Yield 63.5%, m.p. 241–243 C, IR (KBr) cm1: 3291.68,
3078.48, 3064.99, 2951.23, 2936.18, 1600.97, 1558.08,
1236.73; 1H NMR (400 MHz, DMSO-d6) d ppm: 7.98 (s, 1H,
N–H), 7.1–7.53 (m, 6H, Ar–H), 7.68 (d, 2H, Ar–H near
NMe2), 4.96 (d, 1H, N–CH), 4.51 (d, 1H, N–CH), 2.86 (s,
6H, CH3), 2.69 (s, 3H, CH3).
13C NMR (DMSO-d6) d ppm;
23.8, 40.91, 53.6, 128.6, 135.2, 139.7, 147.2, 150.8, 158.3;
MS: m/z 377.32 [M+1].
2.3.8. 3-(4-Bromophenyl)-6-(p-tolyl)-3, 3a-dihydo-2H-pyrazolo
[30,40:4,5] thiazolo[3,2-b] [1,2,4]-triazole (4h)
Yield: 58.6%; m.p. 226–228 C; IR (KBr) cm1: 3285.27,
3073.51, 3064.99, 2951.23, 1600.97, 1558.08, 1236.73; 1H
NMR (400MHz, DMSO-d6) d ppm: 7.98 (s, 1H, N–H), 7.05–
7.61(m, 6H, Ar–H), 6.91 (d, 2H, Ar–H), 4.81 (d, 1H, N–
CH), 4.55 (d, 1H, S-CH), 2.79 (s, 3H, CH3);
13C NMR(DMSO-d6) d ppm: 22.9, 41.5, 52.9, 121.8, 124.5, 131.09,
133.6, 142.3, 147.2, 158.7; MS: m/z 413.92 [M+ 2], 412.87
[M+1].
2.3.9. 3-Phenyl-6-(p-tolyl)-3, 3a-dihydro-isoxazolo [30,40: 4,5]
thiazolo [3,2-b] [1,2,4] triazole (5a)
A mixture of compound 3a (0.005 mol), hydroxylamine hydro-
chloride (0.005 mol) and anhydrous CH3COONa (0.01 mol) in
glacial acetic acid was heated under reﬂux conditions for 6 h.
Concentrated and cooled, the brown colour solid separated
was ﬁltered, washed well with water and recrystallized from
glacial acetic acid as brown crystals. Yield ﬃ 68%, m.p. 249–
51 C; IR (KBr) cm1: 3038.63, 3057.16, 2929.95, 1537.08,
1238.68, 920.42, 677.21; 1H NMR (400 MHz, DMSO-d6)
d ppm: 7.09–7.48 (m, 9H, Ar–H), 5.37 (d, 1H, CH–O), 4.71
(d, 1H, S–CH), 2.38 (s, 3H, CH3);
13C NMR (DMSO-d6)
d ppm: 22.3, 35.1, 71.7, 124.3, 126.8, 130.4, 134.2, 138.9,
142.3, 151.9, 165.8; MS: m/z 335.26 [M+1].
The other compounds (5b–h) were also prepared similarly
by treating with corresponding compounds 3b–h. The physical
and analytical data were given in Table 1.
2.3.10. 3-(4-Chlorophenyl)-6-(p-tolyl)-3, 3a-dihydo isoxazolo
[30,40:4,5] thiazolo[3,2-b] [1,2,4]-triazole (5b)
Yield: 67.1%, m.p. 265–267 C; IR (KBr) cm1: 3057.16,
3038.63, 2931.18, 1537.08, 1239.01, 1086.8, 920.42; 1H NMR
414 N. Seelam et al.(400 MHz, DMSO-d6) d ppm: 7.08 (d, 2H, Ar–H near Cl),
7.12–7.41 (m, 6H, Ar–H), 5.37 (d, 1H, O–CH), 4.71 (d, 1H,
S–CH), 2.41 (s, 3H, CH3).
13C NMR (DMSO-d6) d ppm:
22.3, 35.1, 71.7, 126.8, 129.9, 131.9, 134.2, 138.9, 139.7,
151.9, 165.8; MS: m/z 370.16 [M+ 2], 369.08 [M+1].
2.3.11. 3-(3-Nitrophenyl)-6-(p-tolyl)-3, 3a-dihydo isoxazolo
[30,40:4,5] thiazolo[3,2-b] [1,2,4]-triazole (5c)
Yield: 69.5%, m.p. 225–227 C; IR (KBr) cm1: 3059.11,
3037.01, 2931.18, 1537.08, 1515.63, 1239.01, 918.97; 1H
NMR (400 MHz, DMSO-d6) d ppm: 7.09–7.43 (m, 6H, Ar–
H), 7.59 (d, 2H, Ar–H near NO2), 5.39 (d, 1H, O–CH), 4.68
(d, 1H, S–CH), 2.45 (s, 3H, CH3).
13C NMR (DMSO-d6)
d ppm: 22.3, 35.1, 71.7, 121.4, 126.8, 129.9, 130.4, 134.2,
138.9, 141.6, 148.7, 149.1, 151.9, 165.8; MS: m/z 380.19
[M+1].
2.3.12. 3-(4-Nitrophenyl)-6-(p-tolyl)-3, 3a-dihydo isoxazolo
[30,40:4,5] thiazolo[3,2-b] [1,2,4]-triazole (5d)
Yield: 70.1%; m.p. 261–263 C; IR (KBr) cm1: 3059.11,
3037.01, 2933.27, 1537.08, 1515.63, 1239.01, 1041.85, 920.03;
1H NMR (400 MHz, DMSO-d6) d ppm: 7.09–7.45 (m, 6H,
Ar–H), 7.61 (d, 2H, Ar–H near NO2), 5.41 (d, 1H, O–CH),
4.87 (d, 1H, S–CH), 2.38 (s, 3H, CH3).
13C NMR (DMSO-
d6) d ppm: 22.3, 35.1, 71.7, 121.4, 126.8, 129.9, 130.4, 134.2,
138.9, 148.7, 149.1, 151.9, 165.8; MS: m/z 380.07 [M+1].
2.3.13. 3-(2-Methoxyphenyl)-6-(p-tolyl)-3, 3a-dihydo
isoxazolo [3’,4’:4,5] thiazolo[3,2-b] [1,2,4]-triazole (5e)
Yield: 65.6%, m.p. 241–243 C; IR (KBr) cm1: 3064.52,
3037.01, 2938.16, 1537.08, 1239.01, 1228.78, 1041.85, 918.64;
1H NMR (400 MHz, DMSO-d6) d ppm: 7.05–7.47 (m, 7H,
Ar–H), 6.87 (d, 1H, Ar–H near OCH3), 5.41 (d, 1H, O–CH),
4.87 (d, 1H, S–CH), 3.29 (s, 3H, OCH3), 2.48 (s, 3H, CH3).
13C NMR (DMSO-d6) d ppm: 22.1, 35.1, 54.8, 71.8, 117.9,
121.4, 126.2, 129.9, 134.2, 138.9, 151.9, 159.3, 165.8; MS:
m/z 365.29 [M+1].
2.3.14. 3-(4-Methoxyphenyl)-6-(p-tolyl)-3, 3a-dihydo
isoxazolo [30,40:4,5] thiazolo[3,2-b] [1,2,4]-triazole (5f)
Yield: 68%, m.p. 273–275 C; IR (KBr) cm1: 3064.52,
3037.01, 2938.16, 1537.08, 1239.01, 1228.78, 1038.12, 918.64;
1H NMR (400 MHz, DMSO-d6) d ppm: 7.05–7.47 (m, 7H,
Ar–H), 6.93 (d, 1H, Ar–H near OCH3), 5.41 (d, 1H, O–CH),
4.69 (d, 1H, S–CH), 3.36 (s, 3H, OCH3), 2.48 (s, 3H, CH3).
13C NMR (DMSO-d6) d ppm: 22.1, 35.1, 54.8, 71.8, 117.9,
121.4, 126.2, 129.9, 133.2, 138.9, 151.9, 159.3, 163.2; MS:
m/z 365.4 [M+1].2.3.15. N-N-dimethyl-4-(6-(p-tolyl)-3, 3a-dihydro
isoxazolo[30,40:4,5] thiazolo[3,2-b] [1,2,4]-triazol-3-
yl)aniline(5g)
Yield: 71%, m.p. 256–258 C; IR (KBr) cm1; 3057.12,
3039.81, 2938.16, 2951.08, 1537.08, 1239.33, 1038.12, 919.27;
1H NMR (400 MHz, DMSO-d6) d ppm: 7.71 (d, 1H, Ar–H
near NMe2), 7.11–7.38 (m, 6H, Ar–H), 5.41 (d, 1H, O–CH),
4.68 (d, 1H, S–CH), 2.78 (s, 6H, CH3), 2.37 (s, 3H, CH3).
13C NMR (DMSO-d6) d ppm: 22.3, 35.1, 43.8, 71.2, 111.7,
126.2, 129.9, 131.8, 134.2, 138.9, 145.1, 151.9, 165.1; MS:
m/z 378. 27 [M+1].2.3.16. 3-(4-Bromophenyl)-6-(p-tolyl)-3, 3a-dihydo isoxazolo
[30,40:4,5] thiazolo[3,2-b] [1,2,4]-triazole (5h)
Yield: 60.8%, m.p. 218–220 C; IR (KBr) cm1; 3057.12,
3039.81, 2936.33, 1537.08, 1241.03, 1043.78, 917.26; 1H
NMR (400 MHz, DMSO-d6) d ppm: 7.01–7.41 (m, 8H, Ar–
H), 5.39 (d, 1H, O–CH), 4.73 (d, 1H, S–CH), 2.39 (s, 3H,
CH3).
13C NMR (DMSO-d6) d ppm: 22.3, 35.1, 71.2, 123.6,
126.2, 129.9, 132.6, 134.2, 138.8, 140.3, 150.1, 164.9; MS:
m/z 415.16 [M+ 2], 414.01 [M+1].
3. Results and discussion
3.1. Chemistry
The synthesis of 3-(substituted-phenyl)-6-(p-tolyl)-3, 3a-dihy-
do-2H-pyrazolo [30,40:4,5] thiazolo[3,2-b] [1,2,4]-triazole (4a–
h) and 3-(substituted-phenyl)-6-(p-tolyl)-3, 3a-dihydo isoxazol-
o [30,40:4,5] thiazolo[3,2-b] [1,2,4]-triazole (5a–h) compounds
was prepared by the use of key intermediate 2, condensation
of Ethyl-p-methyl benzoate with thiosemicarbazide at reﬂux
temperature gave 1. The synthesis of 5-mercapto-3-p-tolyl-S-
triazole 2 was carried out by the cyclization reaction of
compound 1 with 8% NaOH at reﬂux temperature (Scheme 1).
Compound 2 was then reacted with chloroaceticacid, appro-
priate aldehydes and acetic anhydride in the presence of anhy-
drous sodium acetate in glacial AcOH at reﬂux temperature to
give chalcone derivatives of 2-(p-tolyl) thiazolo [3,2-b] [1,2,4]
triazol-6(5H)-one (3a–h). Thus resulted compounds 3a–h were
then converted into title compounds 4a–h and 5a–h by conden-
sation with hydrazine hydrate and hydroxylamine hydrochlo-
ride respectively followed by the literature method25. The
structures of newly synthesized compounds were conﬁrmed
by their IR, 1H NMR, 13C NMR and MS analysis.
In the IR Spectra of compounds 4a–h and 5a–h disappear-
ance of the carbonyl group absorption band at 1700 cm1,
which was present in compound 3 conﬁrmed the cyclization
(or) involvement of a, b-unsaturated carbonyl system. The
N–H band of the pyrazole moiety was observed at about
3290 cm1, and N–O band of isoxazole moiety was observed
at about 920 cm1.
In the 1H NMR spectra of compounds 4a–h and 5a–h re-
corded in DMSO-d6, the signals due to CH–N, CH–O protons
appeared at about d 5 ppm and 5.4 ppm as doublets. On the
other hand the signal due to N–H protons of pyrazole moiety
appeared at about 8 ppm as a singlet. These signals demon-
strate that the cyclization step had occurred as pyrazoles and
isoxazoles. All the other aromatic protons of 4a–h and 5a–h
were observed at the expected regions.
In the 13C NMR spectrum of compounds 4a–h and 5a–h
recovered in DMSO-d6 the signals corresponding to the car-
bons of fused ring compounds observed nearly at about d
22, 41, 53, 58, 121, 126, 128, 139, 141, 147, 158, 165 ppm are
further evidence of their structures. Mass spectra of all of syn-
thesized compounds showed M+/M++1 peaks in agreement
with their molecular formula.
3.2. Antimicrobial activity
The newly prepared synthesized compounds 4a–h and 5a–h
were screened for their anti bacterial activity against Bacillus










































Scheme 1 Synthesis of compounds 4a–h and 5a–h. Reaction conditions: (a) methanol, 10h; (b) 8% NaOH, 5h; (c) chloro acetic acid,
fused CH3COONa, acetic anhydride, glac. AcOH, 4h; (d) hydrazine hydrate, anhyd., CH3COONa, glac. AcOH, 5h and (e) hydroxyl
amine hydrochloride, anhyd., CH3COONa, glac. AcOH, 6h.
Table 2 Antibacterial activity data of synthesized compounds 4a–h and 5a–h.
S.l. No. Minimal Inhibitory Concentration (MIC lg/mL)
B.subtilisa B.thuringiensis a E.coli a P. aeruginosa a
4a 12.5 12.5 12.5 25
4b 3.125 3.125 3.125 3.125
4c 3.125 3.125 6.25 6.25
4d 3.125 3.125 3.125 3.125
4e 12.5 12.5 25 25
4f 12.5 25 25 25
4g 6.25 6.25 12.5 6.25
4h 3.125 3.125 6.25 6.25
5a 25 25 50 50
5b 3.125 6.25 6.25 6.25
5c 3.125 3.125 6.25 12.5
5d 3.125 3.125 3.125 6.25
5e 25 12.5 25 50
5f 25 25 25 25
5g 6.25 6.25 6.25 6.25
5h 3.125 3.125 6.25 6.25
Streptomycin 3.125 6.25 6.25 6.25
Chloramphencol 6.25 6.25 6.25 6.25
a B. subtilis (MTCC No.: 1133), B. thuringiensis (MTCC No.: 4714), E. coli (MTCC No.: 443), and P.aeruginosa (MTCC No.: 2297).
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416 N. Seelam et al.aeruginosa Candida albicans, Aspergillus fumigatus, Bortaris
fabae and Fusarium Oxysporam strains. This activity was deter-
mined by the agar diffusion method and the compounds were
dissolved in DMSO at concentration lmgm1. The activity was
compared with streptomycin and chloramphenicol standard
drugs.
The results depicted in Table 2 revealed that most of the
tested compounds displayed variable inhibitory effects on the
growth of tested Gram-positive and Gram negative bacterial
strains. As usual tested compounds revealed better activity
against Gram-positive bacteria than Gram-negative bacteria.
The antibacterial screened data showed moderate activity of
test compounds. Among the screened 4b, 4c, 4d, 4h, 5b, 5c,
5d, 5g and 5h electron withdrawing groups (–Cl, NO2, Br) have
shown high activity against all the bacterial strains employed. In
this view 4b and 4d were 50%more potent to streptomycin and
chloramphenicol against all the strains employed (MIC
3.125 lg/ml) except B. subtilis organism. In the same way 4c,
4h and 5h were more potent to streptomycin and chloramphen-
icol in inhibiting the growth of B. thuringiensis (MIC 3.125
lg/ml), while its activity was equipotent to streptomycin and
chloramphenicol against E. coli and P. aeruginosa (MIC
6.25 lg/ml) but these compounds were equipotent to strepto-
mycin and more potent to chloramphenicol against B. subtilis
(MIC 3.125 lg/ml). On the other hand 5b was equipotent to
streptomycin against all the strains employed (MIC 3.125
lg/ml, 6.25 lg/ml). Also 5d was more potent to streptomycin
and chloramphenicol against B. thuringiensis and E. coli (MIC
3.125 lg/ml), while its activity was equipotent to Streptomycin
against B. subtilis and P. aeruginosa (MIC 3.125 lg/ml and
6.25 lg/ml). In the same way 5c was more potent to Strepto-
mycin and chloramphenicol against B. thuringiensis (MIC,
3.125 lg/ml) and 50% less potent than streptomycin and chlor-
amphenicol against P. aeruginosa (MIC, 12.5 lg/ml), while its
activity was equipotent to streptomycin against B. subtilis and
E. coli (MIC 3.125 lg/ml and 6.25 lg/ml). In addition 5b, 5c
and 5d were more potent to chloramphenicol against B. subtilis
(MIC 3.125 lg/ml). The remaining compounds have also shown
moderate to good antibacterial activity.Table 3 Antifungal activity data of synthesized compounds 4a–h a
Compound Minimal Inhibitory


















a C. albicans (MTCC No.: 183), A. Fumigatus (MTCC No.: 2550), B. fAll the synthesized compounds of series 4a–h and 5a–h were
evaluated for their antifungal activity against Candida albicans,
Aspergillus fumigatus, Bortaris fabae and fabae and Fusarium
oxysporam fungal strains. The activity was compared with
standard drug Treﬂucan.
The results depicted in Table 3 revealed that most of the
tested compounds displayed variable inhibitory effects on the
growth of tested fungal strains. The screened 4a, 4e, 4f, 5a, 5e
and 5f compounds have shown a highly antifungal activity
against all strains employed. In this view compound 4awas equi-
potent to Treﬂucan against C. albicans (MIC, 3.125 lg/ml),
while its activity was 50% lower than that of Treﬂucan against
all the strains employed (MIC, 6.25 lg/ml). On the other
hand compound 4f, 5a and 5f were equipotent to Treﬂucan
against all the strains employed (MIC, 3.125 lg/ml). Also
compound 5e was 50% lower than Treﬂucan against
F. oxysporam (MIC, 6.25 lg/ml), while its activity was equipo-
tent to Treﬂucan against C. albicans, A. fumigatus and B. fabae
(MIC, 3.125 lg/ml). The remaining compounds have also
shown moderate to good antifungal activity against all the
strains employed.
3.3. Antitubercular studies
All the synthesized compounds of series 4a–h and 5a–h were
evaluated for their anti tubercular activity. Drug susceptibility
and determination of MIC of the test compounds against
Mycobacterium tuberculosis H37Rv were performed by the
agar micro dilution method, where two fold dilutions of each
test compound were added into 7H10 agars supplemented with
OADC and organism. A culture of used microorganism M.
tuberculosis H37Rv growing on the L–J medium was harvested
in 0.85% saline with 0.05% Tween-80. A suspension of com-
pounds was prepared in DMSO. This suspension was added
to (in tubes) 7H10 middle brook’s medium (containing
1.7 ml medium and 0.2 ml OADC supplement) at different
concentrations of compound keeping the volume constant,
that is, 0.1 ml medium was allowed to cool keeping the tubes
in the slanting position. These tubes were then incubated atnd 5a–h.
Concentration (MIC lg/mL)


















abae (ATCC No.: 14862) and F. oxysporam (MTCC No.: 7392).
Table 4 Antitubercular activity data of synthesized com-
pounds 4a–h and 5a–h.
Compound MIC (lg/ml) Compound MIC (lg/ml)
4a >12.5 5a 50
4b 3.125 5b 6.25
4c 6. 25 5c >6.25
4d 3.125 5d 3.125
4e 25 5e >50
4f >25 5f >50
4g >6.25 5g >12.5
4h >3.125 5h >3.125
Streptomycin 3.125 Streptomycin 3.125
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(5 · 104 bacilli per tube). These tubes were then incubated at
37 C. Growth of bacilli was seen after 30 days of incubation.
Tubes having the compounds were controlled with control
tubes where the medium alone was incubated with H37Rv.
The concentration at which complete inhibition of colonies oc-
curred was taken as active concentration of the test compound.
Streptomycin was used as standard drug. The MIC levels of
some active compounds (4a–h and 5a–h) against these organ-
isms were given in Table 4.
The results depicted in Table 4 revealed that the com-
pounds, displayed variable inhibitory effects on the growth
of the tested M. tuberculosis H37Rv strains.
The antitubercular screened data showed moderate activity
of test compounds. Among the screened 4b, 4d, 4h, 5d and 5h
electron withdrawing groups (–Cl, NO2, Br) have shown high
activity against M. tuberculosis H37Rv.
4. Conclusion
In this communication our aim has been veriﬁed by the
synthesis of 3-(substituted-phenyl)-6-(p-tolyl)-3, 3a-dihydo-
2H-pyrazolo [30,40:4,5] thiazolo[3,2-b] 1,2,4]-triazole 4a–h and
3-(substituted-phenyl)-6-(p-tolyl)-3, 3a-dihydo isoxazolo
[30,40:4,5] thiazolo[3,2-b] [1,2,4]-triazole 5a-h derivatives in
which 1,2,4-triazole and thiazole moieties incorporated with
pyrazole or isoxazole moieties in a single molecular frame-
work. Obtained results revealed that most of the tested com-
pounds showed moderate antimicrobial activity comparable
with the standard drugs. On the other hand the titled com-
pounds showed promising activity as anti-tuberculosis agents.
After all the above ﬁndings it can be concluded that these mol-
ecules become lead molecules for further synthetic and biolog-
ical evaluation.Acknowledgement
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